NIOX Group Plc

AIM:NIOX Stock Report

Market Cap: UK£260.3m

NIOX Group Valuation

Is NIOX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NIOX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: NIOX (£0.65) is trading below our estimate of fair value (£1.06)

Significantly Below Fair Value: NIOX is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NIOX?

Key metric: As NIOX is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for NIOX. This is calculated by dividing NIOX's market cap by their current earnings.
What is NIOX's PE Ratio?
PE Ratio23.7x
EarningsUK£11.00m
Market CapUK£260.28m

Price to Earnings Ratio vs Peers

How does NIOX's PE Ratio compare to its peers?

The above table shows the PE ratio for NIOX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average32.9x
EKF EKF Diagnostics Holdings
24.4xn/aUK£116.6m
SN. Smith & Nephew
35.3x22.5%UK£8.6b
TSTL Tristel
32.3x17.5%UK£209.7m
AMS Advanced Medical Solutions Group
39.5x23.0%UK£439.9m
NIOX NIOX Group
23.7x17.1%UK£260.3m

Price-To-Earnings vs Peers: NIOX is good value based on its Price-To-Earnings Ratio (23.7x) compared to the peer average (32.9x).

Price to Earnings Ratio vs Industry

How does NIOX's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
NIOX 23.7xIndustry Avg. 29.7xNo. of Companies7PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: NIOX is good value based on its Price-To-Earnings Ratio (23.7x) compared to the European Medical Equipment industry average (29.7x).

Price to Earnings Ratio vs Fair Ratio

What is NIOX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NIOX PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio23.7x
Fair PE Ratio26x

Price-To-Earnings vs Fair Ratio: NIOX is good value based on its Price-To-Earnings Ratio (23.7x) compared to the estimated Fair Price-To-Earnings Ratio (26x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NIOX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUK£0.65
UK£0.81
+24.5%
10.1%UK£0.91UK£0.69n/a5
Nov ’25UK£0.63
UK£0.81
+28.8%
10.1%UK£0.91UK£0.69n/a5
Oct ’25UK£0.65
UK£0.81
+24.0%
9.2%UK£0.90UK£0.69n/a5
Sep ’25UK£0.67
UK£0.80
+18.7%
10.5%UK£0.90UK£0.66n/a5
Aug ’25UK£0.63
UK£0.80
+27.0%
10.5%UK£0.90UK£0.66n/a5
Jul ’25UK£0.69
UK£0.78
+13.4%
13.9%UK£0.90UK£0.63n/a4
Jun ’25UK£0.71
UK£0.78
+10.8%
13.9%UK£0.90UK£0.63n/a4
May ’25UK£0.70
UK£0.76
+8.0%
10.5%UK£0.87UK£0.63n/a5
Apr ’25UK£0.64
UK£0.76
+18.8%
10.5%UK£0.87UK£0.63n/a5
Mar ’25UK£0.63
UK£0.76
+19.6%
10.9%UK£0.87UK£0.62n/a5
Feb ’25UK£0.59
UK£0.76
+28.0%
10.9%UK£0.87UK£0.62n/a5
Jan ’25UK£0.67
UK£0.76
+13.4%
10.0%UK£0.87UK£0.62n/a6
Dec ’24UK£0.64
UK£0.76
+18.0%
10.0%UK£0.87UK£0.62n/a6
Nov ’24UK£0.65
UK£0.79
+21.2%
5.9%UK£0.87UK£0.73UK£0.635
Oct ’24UK£0.67
UK£0.79
+18.3%
6.5%UK£0.87UK£0.73UK£0.654
Sep ’24UK£0.69
UK£0.79
+14.8%
7.3%UK£0.87UK£0.71UK£0.674
Aug ’24UK£0.71
UK£0.74
+3.5%
4.1%UK£0.77UK£0.71UK£0.632
Jul ’24UK£0.58
UK£0.69
+18.8%
11.0%UK£0.79UK£0.61UK£0.693
Jun ’24UK£0.61
UK£0.69
+12.6%
11.0%UK£0.79UK£0.61UK£0.713
May ’24UK£0.46
UK£0.56
+21.2%
1.5%UK£0.57UK£0.55UK£0.703
Apr ’24UK£0.47
UK£0.56
+20.4%
1.5%UK£0.57UK£0.55UK£0.643
Mar ’24UK£0.47
UK£0.49
+4.9%
12.2%UK£0.55UK£0.41UK£0.633
Feb ’24UK£0.39
UK£0.49
+28.1%
12.2%UK£0.55UK£0.41UK£0.593
Jan ’24UK£0.36
UK£0.48
+30.6%
12.0%UK£0.55UK£0.41UK£0.673
Dec ’23UK£0.36
UK£0.48
+30.6%
12.0%UK£0.55UK£0.41UK£0.643
Nov ’23UK£0.38
UK£0.48
+25.8%
12.0%UK£0.55UK£0.41UK£0.653

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Guerbet

€339.2m

Engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions.

0ELV

€27.00

7D

-9.8%

1Y

50.2%

Arjo

SEK 9.2b

Develops and sells medical devices and solutions for patients for clinical and financial outcomes for healthcare in Europe, Asia and Pacific, South America, Africa, and internationally.

0HQ8

SEK 33.92

7D

-4.8%

1Y

-9.6%

Fagron

€1.3b

A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.

0HNZ

€18.06

7D

-6.1%

1Y

5.3%